INS and type 2 diabetes mellitus: Previous studies have failed to illustrate an essential aspect, i.e., if SGLT2i pharmacotherapies for type 2 diabetes have a permissive or additive effect on the dose of insulin [9] and if they exert any impact on the methods used to achieve carbohydrate restrictions.